Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665643 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL714234 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL17260383 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL17646176 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL30317493 | 0.84 | MEN1 (0.53) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL30317257 | 0.82 | MEN1 (0.51) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL11202529 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL11202526 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL21635122 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL16059705 | 0.81 | MEN1 (0.66) | SMN1; SMN2LMNAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011518179-A | — | — | 2011-06-23 | — | — | JP | claimed |
| EP-2279200-A1 | BIOLOGICALLY ACTIVE PEPTIDES | Baxter International Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2009137256-A1 | BIOLOGICALLY ACTIVE PEPTIDES | BAXTER INTERNATIONAL INC. (US) | 2009-11-12 | — | — | WO | claimed |
| EP-0808838-B1 | Sulfur-containing heterocyclic bradykinin antagonists, processes for their production and use thereof | HOECHST AG (DE) | 2003-10-22 | — | — | EP | claimed |
| CN-1112125-A | Acyloxyhexanoic acid derivatives | CIBA GEIGY AG (CH) | 1995-11-22 | — | — | CN | claimed |
| JP-3160985-A | — | — | None | — | — | JP | disclosed |
| JP-6189694-A | — | — | None | — | — | JP | disclosed |
| WO-2025262082-A1 | UNIVERSAL PRINCIPLES OF ACTIVE AND PASSIVE IMMUNIZATION AGAINST VIRAL ANTIGENS | HEIDELBERG BIOTECH GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262023-A1 | PROTEIN OLIGOMERS FOR ACTIVE IMMUNIZATION | HEIDELBERG BIOTECH GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262025-A1 | PHARMACEUTICAL COMPOSITION FOR PASSIVE IMMUNIZATION OR THERAPY | HEIDELBERG BIOTECH GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12428455-B2 | Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-09-30 | — | — | US | disclosed |
| WO-1996011894-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | AKZO NOBEL N.V. (NL) | 1996-04-25 | — | — | WO | disclosed |
| CN-1112125-A | Acyloxyhexanoic acid derivatives | CIBA GEIGY AG (CH) | 1995-11-22 | — | — | CN | disclosed |
| EP-0663897-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE. | AKZO NOBEL NV (NL) | 1995-07-26 | — | — | EP | disclosed |
| EP-0634408-A1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-18 | — | — | EP | disclosed |
| JP-H06189694-A | PRODUCTION OF FOOD AND DRINK | KYOWA HAKKO KOGYO CO LTD | 1994-07-12 | — | — | JP | disclosed |
| WO-1994007814-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | AKZO NOBEL N.V. (NL) | 1994-04-14 | — | — | WO | disclosed |
| JP-H03160985-A | NOVEL VARIANT AND PREPARATION OF SOY SAUCE USING THEREOF | KIKKOMAN CORP | 1991-07-10 | — | — | JP | disclosed |
| EP-0331404-A2 | Method for producing tropane alkaloid | SEITAIKINOU RIYOU KAGAKUHIN SHINSEIZOUGIJUTSU KENKYU KUMIAI (JP) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | SMN1; SMN2 3472/4885LMNA 2458/4885MEN1 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.